Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Co
 

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

More...